Evidence map›Paper›PMID 25709558›Full record

ArticleCancer cell international2015

Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals.

Abdel-Moneim M Osman, Suad A Telity, Saud A Telity, Zoheir A Damanhouri, Sameer E Al-Harthy, Huda M Al-Kreathy, Wafaa S Ramadan, Mohamed F Elshal, Lateef M Khan, Fatemah Kamel

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Implication of MAPK, Lipocalin-2, and Fas in the protective action of liposomal resveratrol against isoproterenol-induced kidney injury.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Oleuropein Ameliorates Cisplatin-induced Hematological Damages Via Restraining Oxidative Stress and DNA Injury.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017
    Article
  14. Article
  15. Article
  16. Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity.Oxidative medicine and cellular longevity · 2016
    Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Abdel-Moneim M OsmanPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia ; Pharmacology unit, National Cancer Institute, Cairo University, Cairo, 11796 Egypt.
Suad A Telity
Saud A Telity *Pharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Zoheir A DamanhouriPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Sameer E Al-HarthyPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Huda M Al-KreathyPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Wafaa S RamadanAnatomy Department, Faculty of Medicine, King Abdul Aziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Mohamed F ElshalDepartment of biochemistry, Faculty of science, king abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia ; Molecular Biology and Genetic engineering and Biotechnology Department, Minoufia Universitym Minoufia, Minoufia, Egypt.
Lateef M KhanPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
Fatemah KamelPharmacology Department, Faculty of Medicine, King Abdulaziz University, P.O. box 80205, Jeddah, Saudi Arabia.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin (CIS) is one of the most effective anticancer drug used in the treatment of several solid tumors .Its use is limited by its nephrotoxicity. The present study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of CIS and the possible protective effect against CIS-induced nephrotoxicity in rats.

methodsThe percent survival of female tumor bearing mice was used for determination the cytotoxic activity of CIS in the presence or the absence of RSVL. Uptake and cell cycle effect, serum creatinine (CREA), blood urea nitrogen (BUN), Reduced Glutathione (GSH) and histopatholgical examination of kidney tissues after CIS and/or RSVL therapy were also investigated.

resultsRSVL increased the intracellular level of CIS in EAC cells and there was a strong correlation between the high cellular level of CIS and its cytotoxicity. CIS at a dose level of 5 mg/kg increased the mean survival time of female tumor bearing mice to 25 days compared with 17 days for tumor-bearing control mice. Administration of RSVL at a dose level of 25 mg/kg simultaneously with CIS increased the mean survival time to 48 days with 60% survival of the tumor-bearing animals. Cell cycle analysis of tumor cells showed that CIS treatment decreases the proliferation index of tumor cells while in presence of RSVL there was more significant inhibitions. Also, CIS treatment caused increase in level of creatinine and blood urea with significant decrease in the GSH level. While, in the presence of RSVL, level of creatinine and blood urea restored to control level.

conclusionThis study suggests that RSVL could increase the cytotoxic activity of CIS and protect against its nephrotoxicity.

Indexed as

CisplatinNephroprotectionResveratrol

Identifiers

PMID25709558
PMCPMC4337247
OpenAlexW2098108931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.